Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Pooled analysis of 24-h lung function following treatment with the LAMA/LABA glycopyrronium/formoterol fumarate fixed-dose combination, delivered by a novel MDI co-suspension technology (GFF MDI), in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
Integrated analyses of phase II safety data support the safety of glycopyrrolate-formoterol fumarate (GFF) MDI (PT003) and glycopyrrolate (GP) MDI (PT001) in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013
Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts) Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016
LATE-BREAKING ABSTRACT: Single inhaler triple therapy (ICS/LAMA/LABA) in patients with advanced COPD: Results of the FULFIL trial Source: International Congress 2016 – Biomarkers and phenotypes of COPD and comorbidities Year: 2016
LATE-BREAKING ABSTRACT: A Phase 1b study of PUR0200, a novel tiotropium formulation, in COPD patients Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Inhalation characteristics with Spiromax® (S) versus Turbuhaler® (T) dry powder inhalers (DPI) in healthy adults (HA) and in patients with asthma (A) or COPD Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders Year: 2013
Late Breaking Abstract - Functional respiratory imaging (FRI) and lung function assessment of glycopyrronium/formoterol fumarate dihydrate fixed-dose combination delivered using novel Co-Suspension Delivery Technology (GFF MDI) in COPD Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Enhanced training on how to use a dry powder inhaler (DPI) improves the inhalation manoeuvre (IM) of patients with asthma (child 6–17 yrs and adult >17 yrs) or COPD and in healthy adults (HA) when they use a Spiromax® (S) and Turbuhaler® (T) DPI Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014
LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD Source: International Congress 2015 – Emerging strategies for airway disease treatments Year: 2015
Inspiratory flow resistance of marketed dry powder inhalers (DPI) Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014
LATE-BREAKING ABSTRACT: Exacerbation phenotype directed corticosteroid therapy of COPD: Value of blood eosinophilia (primary results) Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015
Benefit of FDC budesonide (BUD) and formoterol fumarate (FF) FDC delivered by a novel MDI co-suspension technology (BFF MDI), in patients (pts) with moderate-to-severe COPD Source: International Congress 2016 – Pharmacological management of COPD Year: 2016
Onset of action of formoterol/budesonide (F/B) Spiromax® compared with F/B Turbuhaler® in patients with COPD: A preliminary report Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016
LATE-BREAKING ABSTRACT: Indacaterol/glycopyrronium (IND/GLY) reduces the risk of exacerbations versus salmeterol/fluticasone (SFC) in moderate-to-very severe COPD patients irrespective of prior ICS/LABA/LAMA therapy: The FLAME study Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016
Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
TIOSPIR®: Large scale trial of tiotropium Respimat® vs HandiHaler® (HH) in patients (pts) with COPD Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS) Source: International Congress 2016 – Best abstracts in asthma and COPD Year: 2016